ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,619.56
0.20%
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs Yen
157.25
0.00%
Brent Oil
81.295
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) ニュース

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:EPRX
日付受信時刻ニュースソース見出しコード企業名
2024/05/2406 : 04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/2406 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/2406 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/2220 : 04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/2220 : 00PR Newswire (US)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/2220 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/2206 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/2206 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/2206 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/1601 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/1420 : 04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/1420 : 00PR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/1420 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/0906 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/0906 : 03PR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/0906 : 03PR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/0220 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/05/0220 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/04/1120 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/04/1120 : 00PR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/04/0820 : 00PR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/04/0820 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/04/0520 : 00PR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayNASDAQ:EPRXEupraxia Pharmaceuticals Inc
2024/04/0520 : 00PR Newswire (Canada)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayNASDAQ:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EPRX

最近閲覧した銘柄

NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
NKE
Nike
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MCD
McDonalds
FX
USDJPY
US Dollar vs Yen
NASDAQ
TSLA
Tesla
NYSE
CVX
Chevron
NYSE
DIS
Walt Disney
AMEX
XLV
Health Care Select Sector
AMEX
XLF
Financial Select Sector
NYSE
JPM
JP Morgan Chase
NASDAQ
AMZN
Amazon.com
USOTC
BASFY
BASF (QX)
NYSE
XOM
Exxon Mobil
CCOM
SILVER
SILVER
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有